Concert Pharmaceuticals Inc
$
10.82
-0.55 (-4.84%)
| Volume: | 144,458 | Avg Vol (1m): | 351,385 |
| Market Cap $: | 257.47 Mil | Enterprise Value $: | 98.44 Mil |
| P/E (TTM): | 0.00 | P/B: | 1.68 |
| Earnings Power Value | -15338.07 |
| Net Current Asset Value | 5.45 |
| Tangible Book | 6.37 |
| Projected FCF | 5.83 |
| Median P/S Value | 0.95 |
| Graham Number | 0 |
| Peter Lynch Value | 0 |
| DCF (FCF Based) | 0 |
| DCF (Earnings Based) | 0 |
1Y (-%)
Manual of Stocks™ Web
Financial Strength : 9/10
GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
| Current | vs industry | vs history | |
|---|---|---|---|
| Cash-to-Debt | No Debt |
Cash-To-Debt ranked
higher than
75.32%
of
1078
companies
in the
Biotechnology
industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
CNCE:
No Debt
Ranked among companies with meaningful Cash-To-Debt only.
|
Cash-To-Debt range over the past 10 years
Min: 1.34, Med: 10000, Max: 10000
Current: 10000
|
| Equity-to-Asset | 0.82 |
Equity-to-Asset ranked
higher than
86.11%
of
763
companies
in the
Biotechnology
industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
CNCE:
0.82
Ranked among companies with meaningful Equity-to-Asset only.
|
Equity-to-Asset range over the past 10 years
Min: -3.22, Med: 0.85, Max: 0.93
Current: 0.82
|
| Interest Coverage | No Debt |
Interest Coverage ranked
lower than
72.40%
of
500
companies
in the
Biotechnology
industry.
Industry Max: 22756408, Med: 10000, Min: 0.12
CNCE:
No Debt
Ranked among companies with meaningful Interest Coverage only.
|
Interest Coverage range over the past 10 years
Min: 80.22, Med: 5056.84, Max: 10000
Current: 10000
|
| Piotroski F-Score | 2 |
0
1
2
3
4
5
6
7
8
9
| |
| Altman Z-Score | 3.47 |
DISTRESS
GREY
SAFE
| |
| Beneish M-Score | -19.60 |
Not Manipulator
Manipulator
| |
| WACC vs ROIC % |
ROIC -1385.45%
WACC 5.15%
| ||
Profitability & Growth : 1/10
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
| Current | vs industry | vs history | |
|---|---|---|---|
| Operating Margin % | -7000.10 |
Operating Margin ranked
higher than
97.73%
of
792
companies
in the
Biotechnology
industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
CNCE:
-7000.1
Ranked among companies with meaningful Operating Margin only.
|
Operating Margin range over the past 10 years
Min: -29406.32, Med: -101.56, Max: 64.39
Current: -7000.1
|
| Net Margin % | -7118.04 |
Net Margin ranked
higher than
97.10%
of
792
companies
in the
Biotechnology
industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
CNCE:
-7118.04
Ranked among companies with meaningful Net Margin only.
|
Net Margin range over the past 10 years
Min: -29149.43, Med: -108.63, Max: 66.47
Current: -7118.04
|
| ROE % | -40.15 |
ROE ranked
higher than
98.08%
of
989
companies
in the
Biotechnology
industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
CNCE:
-40.15
Ranked among companies with meaningful ROE only.
|
ROE range over the past 10 years
Min: -46.91, Med: -2.35, Max: 67.51
Current: -40.15
|
| ROA % | -35.53 |
ROA ranked
higher than
98.80%
of
1084
companies
in the
Biotechnology
industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
CNCE:
-35.53
Ranked among companies with meaningful ROA only.
|
ROA range over the past 10 years
Min: -51.03, Med: -25.32, Max: 61.28
Current: -35.53
|
| ROC (Joel Greenblatt) % | -724.38 |
ROC (Joel Greenblatt) ranked
higher than
98.36%
of
1036
companies
in the
Biotechnology
industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
CNCE:
-724.38
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
|
ROC (Joel Greenblatt) range over the past 10 years
Min: -2231.9, Med: -362.86, Max: 4406.69
Current: -724.38
|
| 3-Year Total Revenue Growth Rate | -46.00 |
3-Year Revenue Growth Rate ranked
higher than
96.16%
of
651
companies
in the
Biotechnology
industry.
Industry Max: 906.3, Med: 1.1, Min: -100
CNCE:
-46.8
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
|
3-Year Revenue Growth Rate range over the past 10 years
Min: -82.4, Med: -32.2, Max: 124.7
Current: -46.8
|
» CNCE's 30-Y Financials
Financials (Next Earnings Date: 2019-08-02)
Guru Trades Click for details
Guru Trades in
SEC Filings
Gurus Latest Trades with NAS:CNCE
» Interactive Chart
Peter Lynch Chart
Business Description
| Industry | Biotechnology » Biotechnology   NAICS : 325412   SIC : 2834 |
| Compare | NAS:PTGX NAS:XFOR NAS:MRSN NAS:TOCA NAS:XENE XTAE:KMDA NAS:ZYNE XTER:MDG1 NAS:ATHX NAS:CALA NAS:UROV XBRU:CYAD NAS:NVAX NAS:CERC NAS:MRKR SHSE:603139 NAS:PETX AMEX:XXII TPE:1760 AMEX:OCX |
| Traded in other countries | 73C.Germany |
| Address | 65 Hayden Avenue, Suite 3000N, Lexington, MA, USA, 02421 |
| Concert Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company aims to discover and develop small-molecule drugs by incorporating new elements into known molecules or by leveraging the current approved drugs to be used for new treatments. The pipeline consists of small molecules designed for oral administration to cure cystic fibrosis, inflammation, narcolepsy, residual schizophrenia, major depressive disorder, and Alzheimer's agitation. | |
Ratios
| Current | vs industry | vs history | |
|---|---|---|---|
| PB Ratio | 1.68 |
PB Ratio ranked
higher than
76.92%
of
962
companies
in the
Biotechnology
industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
CNCE:
1.68
Ranked among companies with meaningful PB Ratio only.
|
PB Ratio range over the past 10 years
Min: 1.48, Med: 2.48, Max: 5.31
Current: 1.68
|
| PS Ratio | 245.91 |
PS Ratio ranked
higher than
84.71%
of
726
companies
in the
Biotechnology
industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
CNCE:
245.91
Ranked among companies with meaningful PS Ratio only.
|
PS Ratio range over the past 10 years
Min: 2.28, Med: 21.54, Max: 3777.5
Current: 245.91
|
| EV-to-EBIT | -1.37 |
EV-to-EBIT ranked
higher than
86.59%
of
261
companies
in the
Biotechnology
industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
CNCE:
-1.37
Ranked among companies with meaningful EV-to-EBIT only.
|
EV-to-EBIT range over the past 10 years
Min: -6.7, Med: -2.25, Max: 24.3
Current: -1.37
|
| EV-to-EBITDA | -1.40 |
EV-to-EBITDA ranked
higher than
87.54%
of
281
companies
in the
Biotechnology
industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
CNCE:
-1.4
Ranked among companies with meaningful EV-to-EBITDA only.
|
EV-to-EBITDA range over the past 10 years
Min: -7.1, Med: -2.3, Max: 23.4
Current: -1.4
|
| EV-to-Revenue | 95.46 |
EV-to-Revenue ranked
higher than
94.55%
of
771
companies
in the
Biotechnology
industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
CNCE:
95.46
Ranked among companies with meaningful EV-to-Revenue only.
|
EV-to-Revenue range over the past 10 years
Min: -0.7, Med: 11.2, Max: 3255.3
Current: 95.46
|
| Current Ratio | 20.44 |
Current Ratio ranked
higher than
96.83%
of
1074
companies
in the
Biotechnology
industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
CNCE:
20.44
Ranked among companies with meaningful Current Ratio only.
|
Current Ratio range over the past 10 years
Min: 2.14, Med: 17.48, Max: 33.89
Current: 20.44
|
| Quick Ratio | 20.44 |
Quick Ratio ranked
higher than
96.83%
of
1074
companies
in the
Biotechnology
industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
CNCE:
20.44
Ranked among companies with meaningful Quick Ratio only.
|
Quick Ratio range over the past 10 years
Min: 2.14, Med: 17.48, Max: 33.89
Current: 20.44
|
| Days Sales Outstanding | 3.89 |
Days Sales Outstanding ranked
higher than
99.85%
of
668
companies
in the
Biotechnology
industry.
Industry Max: 1096.56, Med: 64.17, Min: 0.06
CNCE:
3.89
Ranked among companies with meaningful Days Sales Outstanding only.
|
Days Sales Outstanding range over the past 10 years
Min: 0.37, Med: 1.48, Max: 56.64
Current: 3.89
|
Dividend & Buy Back
| Current | vs industry | vs history | |
|---|---|---|---|
| 3-Year Share Buyback Rate | -1.80 |
3-Year Share Buyback Rate ranked
higher than
65.58%
of
857
companies
in the
Biotechnology
industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
CNCE:
-1.8
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
|
3-Year Share Buyback Rate range over the past 10 years
Min: -25.5, Med: -9, Max: -1.8
Current: -1.8
|
Valuation & Return
| Current | vs industry | vs history | |
|---|---|---|---|
| Price-to-Tangible-Book | 1.70 |
Price-to-Tangible-Book ranked
higher than
82.44%
of
894
companies
in the
Biotechnology
industry.
Industry Max: 800, Med: 5.32, Min: 0.05
CNCE:
1.7
Ranked among companies with meaningful Price-to-Tangible-Book only.
|
Price-to-Tangible-Book range over the past 10 years
Min: 1.69, Med: 2.61, Max: 5.13
Current: 1.7
|
| Price-to-Projected-FCF | 1.86 |
Price-to-Intrinsic-Value-Projected-FCF ranked
lower than
100.00%
of
193
companies
in the
Biotechnology
industry.
Industry Max: 117, Med: 3.12, Min: 0.09
CNCE:
1.86
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
|
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 1.85, Med: 1.95, Max: 2.07
Current: 1.86
|
| Price-to-Median-PS-Value | 11.39 |
Price-to-Median-PS-Value ranked
higher than
88.94%
of
678
companies
in the
Biotechnology
industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
CNCE:
11.39
Ranked among companies with meaningful Price-to-Median-PS-Value only.
|
Price-to-Median-PS-Value range over the past 10 years
Min: 0.09, Med: 1.09, Max: 174.38
Current: 11.39
|
| Earnings Yield (Joel Greenblatt) % | -74.06 |
Earnings Yield (Greenblatt) ranked
higher than
96.76%
of
1081
companies
in the
Biotechnology
industry.
Industry Max: 5000, Med: -7.73, Min: -10000
CNCE:
-74.06
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
|
Earnings Yield (Greenblatt) range over the past 10 years
Min: -116, Med: -18.6, Max: 2313.9
Current: -74.06
|
More Statistics
| Revenue (TTM) (Mil) $ | 1.03 |
| EPS (TTM) $ | -3.13 |
| Beta | 0.46 |
| Volatility % | 38.28 |
| 52-Week Range $ | 9.21 - 20.79 |
| Shares Outstanding (Mil) | 23.8 |
Analyst Estimate
Piotroski F-Score Details
| Piotroski F-Score | 2 |
| Positive ROA | N |
| Positive CFROA | N |
| Higher ROA yoy | N |
| CFROA > ROA | Y |
| Lower Leverage yoy | Y |
| Higher Current Ratio yoy | N |
| Less Shares Outstanding yoy | N |
| Higher Gross Margin yoy | N |
| Higher Asset Turnover yoy | N |